PharmX Technologies Limited

CHIA:PHX Stock Report

Market Cap: AU$80.9m

PharmX Technologies Past Earnings Performance

Past criteria checks 0/6

PharmX Technologies's earnings have been declining at an average annual rate of -45.6%, while the Software industry saw earnings growing at 15.4% annually. Revenues have been declining at an average rate of 11.3% per year.

Key information

-45.60%

Earnings growth rate

-50.52%

EPS growth rate

Software Industry Growth22.05%
Revenue growth rate-11.28%
Return on equity-1.66%
Net Margin-3.51%
Last Earnings Update30 Jun 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How PharmX Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CHIA:PHX Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 258010
31 Mar 258020
31 Dec 249030
30 Sep 248030
30 Jun 248030
31 Mar 247020
31 Dec 236010
30 Sep 236010
30 Jun 236-120
31 Dec 222-120
30 Sep 224-120
30 Jun 225010
31 Mar 221201-1
31 Dec 211201-1
30 Sep 211211-1
30 Jun 211211-1
31 Mar 211211-1
31 Dec 201111-1
30 Sep 201111-1
30 Jun 201101-1
31 Mar 2011-110
31 Dec 1910-210
30 Sep 1911-310
30 Jun 1911-410
31 Mar 1912-31-1
31 Dec 1812-21-1
30 Sep 1812-11-1
30 Jun 181301-1
31 Mar 1813-31-1
31 Dec 1714-61-1
30 Sep 1714-61-2
30 Jun 1715-62-2
31 Mar 1715-32-2
31 Dec 161612-2
30 Sep 161602-2
30 Jun 161702-2
31 Mar 161711-2
31 Dec 151710-1
30 Sep 151830-1
30 Jun 1518510
31 Mar 1518520
31 Dec 1418520

Quality Earnings: PHX is currently unprofitable.

Growing Profit Margin: PHX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PHX is unprofitable, and losses have increased over the past 5 years at a rate of 45.6% per year.

Accelerating Growth: Unable to compare PHX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PHX is unprofitable, making it difficult to compare its past year earnings growth to the Software industry (24%).


Return on Equity

High ROE: PHX has a negative Return on Equity (-1.66%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/14 12:05
End of Day Share Price 2025/11/14 00:00
Earnings2025/06/30
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PharmX Technologies Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Caleb WengPAC Partners Securities Pty. Ltd.